Please assess the completion status of the following clinical trial:

Trial Title: Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed aggressive B-cell non-Hodgkin's lymphoma, including the following subtypes:~  * Grade 3 follicular lymphoma~ * Diffuse B-cell lymphoma, including diffuse large cell lymphoma with the following variants:~    * Centroblastic~   * Immunoblastic~   * Plasmablastic~   * Anaplastic large cell~   * T-cell-rich B-cell lymphoma~ * Primary effusion lymphoma~ * Intravascular B-cell lymphoma~ * Primary mediastinal B-cell lymphoma~ * Burkitt's or Burkitt-like lymphoma~ * Mantle cell lymphoma (blastoid)~ * Aggressive marginal zone lymphoma (monocytoid)~* Previously untreated disease~* CD20-positive disease~* International prognostic index (IPI) score 0 or 1 (age-adjusted)~  * Only patients with bulky disease, as defined by largest single or conglomerate tumor ≥ 7.5 cm in diameter, are allowed to have an IPI score of 0~* No mucosa-associated lymphoid tissue (MALT) lymphoma~* No CNS involvement of lymphoma (intracerebral, meningeal, or intraspinal)~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Platelet count ≥ 100,000/mm³~* WBC ≥ 2,500/mm³~* No known hypersensitivity to the study medications~* No known HIV-positivity~* No active hepatitis infection~* Not pregnant or lactating~* Negative pregnancy test~* No other malignancy within the past 5 years except carcinoma in situ or basal cell skin cancer~* No impaired left ventricular function~* No severe cardiac arrhythmias~* No other impaired organ function~* No other serious disorder~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy or radiotherapy~* No prior immunosuppressive treatment with cytostatics~* No concurrent participation in other treatment studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Interventional: 6 R-CHOP-21 (Type: ACTIVE_COMPARATOR): Arm I (R-CHOP-21): Patients receive R-CHOP immunochemotherapy comprising rituximab IV, cyclophosphamide IV over 15 minutes, doxorubicin IV, and vincristine IV on day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
- Interventional: 6 R-CHOP-21 + radiotherapy (Type: ACTIVE_COMPARATOR): Arm II (R-CHOP-21 and radiotherapy): Patients receive R-CHOP as in arm I. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning 2-6 weeks after the last course of R-CHOP, patients who achieve a complete remission (CR) undergo radiotherapy 5 days a week for approximately 5½ weeks.
- Interventional: 6 R-CHOP-14 (Type: ACTIVE_COMPARATOR): Arm III (R-CHOP-14): Patients receive R-CHOP as in arm I. Patients also receive filgrastim (G-CSF) subcutaneously once daily on days 4-13 or until blood counts recover. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
- Interventional: 6 R-CHOP-14 and radiotherapy (Type: ACTIVE_COMPARATOR): Arm IV (R-CHOP-14 and radiotherapy): Patients receive R-CHOP as in arm I. Patients also receive G-CSF an in arm III. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning 2-6 weeks after the last course of R-CHOP, patients who achieve CR undergo radiotherapy as in arm II.

Based on this trial design, predict the completion outcome and termination type (if applicable).